Relapse of Escherichia coli meningitis following therapy with moxalactam.
Bacteriologic relapse occurred in a premature infant with Escherichia coli K1 meningitis 11 days following the completion of a 3-week course of therapy with the new 1-oxa-beta-lactam antibiotic moxalactam. Therapeutic failure was most probably the result of sequestration of viable bacteria in ventricular and/or paraventricular sites. While in vitro data and preliminary clinical evaluation of the new beta-lactam antibiotics indicate that these agents may be useful in the treatment of neonatal Gram-negative enteric meningitis, undue optimism regarding their efficacy, as with former agents, may be unwarranted.
D002511:Cephalosporins / Q000627:therapeutic use*; D002513:Cephamycins / Q000627:therapeutic use*; D004927:Escherichia coli Infections / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy*; D008297:Male; D008581:Meningitis / Q000188:drug therapy*; D009070:Moxalactam; D012008:Recurrence
D002511:Cephalosporins; D002513:Cephamycins; D009070:Moxalactam